Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus Fumaderm in systemic-therapy-naive moderate to severe plaque psoriasis
2016-003718-28Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in plaque psoriasis and psoriasis comparing Risankizumab with Fumaderm (2 arms). Primary endpoint: PASI 90 at Week 24. Started Apr 2017; status: completed.
02
Drugs
risankizumabFumaderm
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2016-003718-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003718-28.